title: Enhancement of the pulmonary allergic granulocyte recruitment in rats exposed to DMTI-II, a Kunitz-type inhibitor isolated from Dimorphandra mollis seeds.
abstract: DMTI-II (23-kDa trypsin inhibitor purified from Dimorphandra mollis seeds) promotes acute inflammation accompanied by an early infiltration of eosinophils, a critical cell type involved in allergic diseases. We have evaluated here the capacity of DMTI-II to enhance the allergic pulmonary inflammation, looking over time to the leukocyte trafficking from bone marrow to peripheral blood, and their recruitment into the allergic airways. Male Wistar rats were sensitized and challenged with ovalbumin (OVA). At 2 to 16h prior to OVA challenge, animals were exposed to DMTI-II (10μg). Bronchoalveolar lavage fluid (BAL), circulating blood and bone marrow were examined at 24h post-OVA challenge. Challenge with OVA significantly increased the influx of total inflammatory cells, neutrophils and eosinophils in BAL and lung tissue. Pre-exposure to DMTI-II potentiated total inflammatory cell and neutrophil recruitment (p<0.05). Neutropoiesis and neutrophilia accompanied pulmonary cell influx. Pre-exposure to DMTI-II also significantly increased eosinophil recruitment to BAL, an effect starting at 4h, remaining markedly elevated at 16h (p<0.05). Eosinopoiesis and eosinophilia (seen within 2 to 4h) were also observed. Exposure to DMTI-II alone increased the IL-4 levels, and further increased the IL-4 levels in OVA-challenged rats. The levels of IgE, LTB(4) and eotaxin in OVA-challenged rats were greater compared with non-sensitized rats, but DMTI-II exposure failed to further enhance such levels. In summary, our study shows that DMTI-II itself presents granulocytopoietic activity, and enhances allergen-induced neutrophil and eosinophil mobilization from bone marrow to lung tissues that is accompanied by enhanced IL-4 production.
authors.affiliation: Department of Pharmacology, Faculty of Medical Sciences, University of Campinas, Campinas (SP), Brazil.
authors.forename: Glaucia C
authors.initials: GC
authors.lastname: Mello
authors.forename: Karina F
authors.initials: KF
authors.lastname: Ruiz
authors.forename: Dalize M
authors.initials: DM
authors.lastname: Squebola
authors.forename: André A
authors.initials: AA
authors.lastname: Schenka
authors.forename: Ivani A
authors.initials: IA
authors.lastname: de Souza
authors.forename: Maria Lígia R
authors.initials: ML
authors.lastname: Macedo
authors.forename: Edson
authors.initials: E
authors.lastname: Antunes
mesh_terms: D000818:Animals; D018893:Bronchoalveolar Lavage; D002454:Cell Differentiation / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004804:Eosinophils / Q000473:pathology; D007887:Fabaceae; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D015847:Interleukin-4 / Q000378:metabolism*; D008168:Lung / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008297:Male; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D010047:Ovalbumin / Q000008:administration & dosage; D010940:Plant Proteins / Q000008:administration & dosage* / Q000737:chemistry; D011014:Pneumonia / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D012639:Seeds; D014361:Trypsin Inhibitors / Q000008:administration & dosage* / Q000737:chemistry
chemical_list: D010940:Plant Proteins; D014361:Trypsin Inhibitors; D015847:Interleukin-4; D007073:Immunoglobulin E; D010047:Ovalbumin